Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Print PDF (324K) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (54)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Fluiter, K.
Right arrow Articles by Baas, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fluiter, K.
Right arrow Articles by Baas, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 2003, Vol. 31, No. 3 953-962
© 2003 Oxford University Press

In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides

Kees Fluiter, Anneloor L. M. A. ten Asbroek, Marit B. de Wissel, Marja E. Jakobs, Margit Wissenbach1, Håkan Olsson1, Otto Olsen1, Henrik Oerum1 and Frank Baas*

Department of Neurogenetics, Academical Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands and 1 Cureon A/S, Fruebjergvej 3, DK-2100 Copenhagen, Denmark

*To whom correspondence should be addressed. Tel: +31 20 5665998; Fax: +31 20 5669312; Email: f.baas{at}amc.uva.nl

Locked nucleic acids (LNA) are novel high-affinity DNA analogs that can be used as genotype-specific drugs. The LNA oligonucleotides (LNA PO ODNs) are very stable in vitro and in vivo without the need for a phosphorothiolated backbone. In this study we tested the biological fate and the efficacy in tumor growth inhibition of antisense oligonucleotides directed against the gene of the large subunit of RNA polymerase II (POLR2A) that are completely synthesized as LNA containing diester backbones. These full LNA oligonucleotides strongly reduce POLR2A protein levels. Full LNA PO ODNs appeared to be very stable compounds when injected into the circulation of mice. Full LNA PO ODNs were continuously administered for 14 days to tumor-bearing nude mice. Tumor growth was inhibited sequence specifically at dosages from 1 mg/kg/day. LNA PO ODNs appeared to be non-toxic at dosages <5 mg/kg/day. Biodistribution studies showed the kidneys to have the highest uptake of LNA PO ODNs and urinary secretion as the major route of clearance. This report shows that LNA PO ODNs are potent genotype-specific drugs that can inhibit tumor growth in vivo.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
J. B. Hansen, N. Fisker, M. Westergaard, L. S. Kjaerulff, H. F. Hansen, C. A. Thrue, C. Rosenbohm, M. Wissenbach, H. Orum, and T. Koch
SPC3042: a proapoptotic survivin inhibitor
Mol. Cancer Ther., September 1, 2008; 7(9): 2736 - 2745.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
J. Elmen, M. Lindow, A. Silahtaroglu, M. Bak, M. Christensen, A. Lind-Thomsen, M. Hedtjarn, J. B. Hansen, H. F. Hansen, E. M. Straarup, et al.
Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver
Nucleic Acids Res., March 27, 2008; 36(4): 1153 - 1162.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. R. Dass, P. F.M. Choong, and L. M. Khachigian
DNAzyme technology and cancer therapy: cleave and let die
Mol. Cancer Ther., February 1, 2008; 7(2): 243 - 251.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. F. Corsten, R. Miranda, R. Kasmieh, A. M. Krichevsky, R. Weissleder, and K. Shah
MicroRNA-21 Knockdown Disrupts Glioma Growth In vivo and Displays Synergistic Cytotoxicity with Neural Precursor Cell Delivered S-TRAIL in Human Gliomas
Cancer Res., October 1, 2007; 67(19): 8994 - 9000.
[Abstract] [Full Text] [PDF]

Home page
 RNAHome page
A. Aartsma-Rus and G.-J. B. van Ommen
Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications
RNA, October 1, 2007; 13(10): 1609 - 1624.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
R. Bhindi, R. G. Fahmy, H. C. Lowe, C. N. Chesterman, C. R. Dass, M. J. Cairns, E. G. Saravolac, L.-Q. Sun, and L. M. Khachigian
Brothers in Arms: DNA Enzymes, Short Interfering RNA, and the Emerging Wave of Small-Molecule Nucleic Acid-Based Gene-Silencing Strategies
Am. J. Pathol., October 1, 2007; 171(4): 1079 - 1088.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
M. Negrini, M. Ferracin, S. Sabbioni, and C. M. Croce
MicroRNAs in human cancer: from research to therapy
J. Cell Sci., June 1, 2007; 120(11): 1833 - 1840.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
O. R. Mook, F. Baas, M. B. de Wissel, and K. Fluiter
Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo
Mol. Cancer Ther., March 1, 2007; 6(3): 833 - 843.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
V. Rapozzi, S. Cogoi, and L. E. Xodo
Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.
Mol. Cancer Ther., July 1, 2006; 5(7): 1683 - 1692.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
E. Brunet, M. Corgnali, L. Perrouault, V. Roig, U. Asseline, M. D. Sorensen, B. R. Babu, J. Wengel, and C. Giovannangeli
Intercalator conjugates of pyrimidine locked nucleic acid-modified triplex-forming oligonucleotides: improving DNA binding properties and reaching cellular activities
Nucleic Acids Res., July 27, 2005; 33(13): 4223 - 4234.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Brunet, P. Alberti, L. Perrouault, R. Babu, J. Wengel, and C. Giovannangeli
Exploring Cellular Activity of Locked Nucleic Acid-modified Triplex-forming Oligonucleotides and Defining Its Molecular Basis
J. Biol. Chem., May 20, 2005; 280(20): 20076 - 20085.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
A. Valoczi, C. Hornyik, N. Varga, J. Burgyan, S. Kauppinen, and Z. Havelda
Sensitive and specific detection of microRNAs by northern blot analysis using LNA-modified oligonucleotide probes
Nucleic Acids Res., December 14, 2004; 32(22): e175 - e175.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
A. Randazzo, V. Esposito, O. Ohlenschlager, R. Ramachandran, and L. Mayol
NMR solution structure of a parallel LNA quadruplex
Nucleic Acids Res., June 4, 2004; 32(10): 3083 - 3092.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
F. Darfeuille, J. B. Hansen, H. Orum, C. D. Primo, and J.-J. Toulme
LNA/DNA chimeric oligomers mimic RNA aptamers targeted to the TAR RNA element of HIV-1
Nucleic Acids Res., June 4, 2004; 32(10): 3101 - 3107.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
R. G. Fahmy and L. M. Khachigian
Locked nucleic acid modified DNA enzymes targeting early growth response-1 inhibit human vascular smooth muscle cell growth
Nucleic Acids Res., April 23, 2004; 32(7): 2281 - 2285.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
A. Grunweller, E. Wyszko, B. Bieber, R. Jahnel, V. A. Erdmann, and J. Kurreck
Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA
Nucleic Acids Res., June 15, 2003; 31(12): 3185 - 3193.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.